Drug Discovery World

MARCH 2, 2023

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in targeted treatments for cancer and asked what advances the future might bring. She explained the mechanism by which AVA6000 can provide more precise treatment than current chemotherapies.

Therapies 130

Therapies Treatment Trials Disease 130

Drug Discovery World

AUGUST 2, 2024

GLP-1 receptor agonists have dominated the headlines this week, with data revealed on new potential beneficial effects of treatment with semaglutide and dual receptor agonists like pemvidutide. of subjects achieving LFC normalisation after 12 weeks of treatment. relative reduction in liver fat content (LFC), with up to 55.6%

Clinical Trials 130

Clinical Trials Drugs Treatment Disease 130

Drug Discovery World

JULY 11, 2022

David Lewandowski, Business Director of Cell & Gene Therapy at Azenta Life Sciences, explains how efficient sample management can help to work efficiently and bring therapies to market faster. The global cell and gene therapy (CGT) market reached a value of ~$4 billion in 2020 and is expected to grow to ~$34 billion by 2030 1.

Therapies 130

Therapies Clinical Trials Production Trials 130

Drug Discovery World

DECEMBER 12, 2023

Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in a Phase Ib/IIa study. During the trial, EXN407 met all safety and pharmacokinetic parameters and displayed encouraging signals of biological activity.

Small Molecule 130

Small Molecule Trials Pharmacokinetics Treatment 130

Drug Discovery World

DECEMBER 7, 2023

Despite recent leaps forward in our understanding of MND biology, treatment options remain limited. The group examined barriers to translating basic science into effective therapies for MND and suggested guiding principles for future research. The Guiding Principles underpin a new £5 ($6.2)

Bioinformatics 130

Bioinformatics Drugs Clinical Trials Trials 130

Drug Discovery World

MAY 31, 2024

billion by 2030, according to a market research report by Market Research Future. Neuropsychopharmacology profile analysis shows the drug demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms.

Licensing 147

Licensing Licensing FDA Approval Drugs 147

Drug Discovery World

MAY 22, 2023

Not-for-profit medical research organisation LifeArc and techbio company PrecisionLife have agreed a strategic R&D collaboration to accelerate the discovery of targeted treatments for motor neurone disease (MND). MND is also known as amyotrophic lateral sclerosis (ALS) and Lou Gehrig’s disease.

Disease 130

Disease Clinical Trials Laboratories Treatment 130

Drug Discovery World

JULY 31, 2023

DDW’s Reece Armstrong speaks to Hendrik Streefkerk , Chief Medical Officer and Drug Safety Officer of CellProthera about the company’s cell therapy for acute myocardial infarction (AMI) and why regenerative medicine could be key to treating cardiac diseases. million people every year.

Clinical Trials 130

Clinical Trials Hospitals Therapies Trials 130

Drug Discovery World

AUGUST 14, 2023

Lung-I Cheng, Vice President and Head of Cell & Gene Therapy Service Line at AmerisourceBergen, and Cori Gorman, Senior Director of CMC and Regulatory Affairs at Biopharma Excellence, offer advice on navigating the different and sometimes contradictory regulatory requirements in the US and EU. billion in 2020 to $15.5 billion 1.

Marketing 130

Marketing DNA Therapies FDA 130

The Pharma Data

JUNE 28, 2021

Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s (NYSE: LLY) investigational antibody therapy for Alzheimer’s disease (AD). In the US alone, there was an increase of 8 million new caregivers from 2015 to 2020 3.

Therapies 40

Therapies Disease Treatment FDA Approval 40

The Pharma Data

OCTOBER 14, 2021

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). trillion per year by 2030.

Disease 52

Disease Therapies FDA Trials 52

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. ii It is projected that by 2030, close to half of the U.S. Our mission is to create breakthrough therapies that change lives.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

DrugBank

MARCH 7, 2024

adults using obesity medications by 2030, further underlining the growing significance of this sector. Inspired by its success, pharmaceutical companies are pursuing the development of drugs with similar therapeutic profiles, aiming to expand treatment options. Goldman Sachs analysts anticipate a significant rise in the number of U.S.

Pharmaceutical Companies 82

Pharmaceutical Companies Pharmaceuticals Clinical Trials Pharmacokinetics 82

The Pharma Data

MARCH 23, 2023

The new state-of-the-art facility will be the largest of its kind in the country and is expected to be operational by around 2030. Takeda has delivered plasma therapies to meet the needs of patients in Japan for more than 70 years. This represents Takeda’s largest ever investment in manufacturing capacity expansion in Japan.

Therapies 40

Therapies Treatment Vaccine Production 40

DrugBank

MARCH 15, 2024

The weight loss industry has emerged as a major hub for innovative research, groundbreaking treatments, and economic opportunity. billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. With sales soaring to $2.2 for this class of drugs.

Pharmaceutical Companies 69

Pharmaceutical Companies Pharmaceuticals Treatment Marketing 69

Drug Discovery World

OCTOBER 6, 2022

until 2030. It is therefore not surprising that Switzerland played an important role in the global effort to combat the pandemic, and that two Swiss based companies were successful in developing treatments to combat Covid infections (Humabs BioMed/Vir Biotechnology and Molecular Partners/Novartis).” . Valued at $14.8 References: .

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Pharma Companies Marketing 130

Drug Target Review

SEPTEMBER 22, 2023

Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. billion by 2030. Organoids for cell therapy and drug discovery. Cell Stem Cell [Internet]. 2023 May;30(5):571–91. Elsevier; 2020.

Clinical Research 116

Clinical Research Research Drug Development Molecular Biology 116

Drug Discovery World

JANUARY 2, 2024

She believes we might start to see a combination of vaccines with other immunotherapies or classical therapies out there, and that this will become more and more prevalent because of the nature of cancer. He said: “Between now and 2030, we’re going to see a range of vaccines using various technologies.

Research 147

Research Vaccine Science Trials 147

Drug Target Review

DECEMBER 4, 2023

What’s more, investment in this sector is predicted to rise by 70 percent by 2030. Tailoring medical care to a patient’s unique genetic makeup, alongside the close analysis of disease progression, leads to more effective treatments, reduced side effects and faster diagnoses.

Treatment 105

Treatment Science DNA Doctors 105

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). This Refinement Therapeutic Designation reinforces our confidence in gantenerumab, which would be the first subcutaneous specific for the treatment of Alzheimer’s trouble with the prospect for at- home administration.”

Disease 52

Disease FDA Therapies Testimonials 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. Ricks , Lilly chairman and CEO.

Therapies 52

Therapies Hospitals FDA Approval Long-Term Care Facilities 52

Drug Discovery World

DECEMBER 12, 2022

Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening to read in the Guardian 1 that the NHS in the UK believes that by 2030 there will be no new cases of HIV in England. In Nature 3 , we learnt about the CRISPR cancer trial success leading the way to personalised treatments.

Drugs 130

Drugs Engineering Clinical Trials Science 130

The Pharma Data

MAY 26, 2023

With our leading portfolio of medicines in lung cancer, our ambition is to have the right AstraZeneca medicine for more than half of all patients with this disease by 2030. We will showcase significant steps toward that goal with overall survival data from ADAURA that reinforce Tagrisso as the backbone therapy in EGFR-mutated lung cancer.”

Therapies 40

Therapies Trials Treatment Disease 40

The Pharma Data

NOVEMBER 1, 2020

billion by 2030 2. BTK inhibitors have the potential to transform the treatment paradigm of autoimmune diseases including MS. Currently, multi-center, multi-indication clinical trials are underway in the US and China with orelabrutinib as monotherapy or in combination therapies. About InnoCare Pharma.

Clinical Trials 52

Clinical Trials FDA Trials Treatment 52

Vial

MAY 20, 2024

In the field of clinical research , this pipeline can be broken down into several stages and processes specifically designed to rigorously validate the safety and efficacy of new drugs and treatments. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030. What is a Pre-Clinical CRO?

Clinical Research 52

Clinical Research Research Clinical Trials Laboratories 52

Drug Discovery World

APRIL 25, 2023

Spin-out companies play a vital role in translating Cancer Research UK-funded research from the lab into life-saving treatments. Amplify Therapeutics boasts disease-modifying therapies for Gaucher disease and genetic subgroups of Parkinson’s disease. billion by 2030. Anti-ageing science therefore has huge value.

Science 130

Science Small Molecule Disease Government 130

The Pharma Data

SEPTEMBER 28, 2020

Developing next-generation therapies. Assessing an innovative therapy for patients with Chagas cardiomyopathy. Less than 1% of affected individuals receive proper anti-parasitic treatment 11 , and current drugs are inadequate to fight the entire spectrum of the disease. Follow us on social media. Novartis Global Health.

Disease 52

Disease Therapies Treatment Government 52

Drug Discovery World

FEBRUARY 10, 2023

This is reflected in the government’s aim of becoming a leader in the ATMP space by 2030. For instance, Swedish biotech Lokon Pharma worked with the Testa Center for nine weeks on a project to scale up its manufacturing process for its gene therapy candidate. Its value cannot be overstated.

Science 130

Science Drugs Pharmaceutical Companies Pharmaceuticals 130

The Pharma Data

JULY 15, 2021

TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer’s disease in trial participants. The collaboration will introduce a more virtual approach to the evaluation of Alzheimer’s prevention therapies. vice president of pain and neurodegeneration, Lilly.

Trials 52

Trials Clinical Trials Therapies Disease 52

The Pharma Data

MARCH 31, 2022

“As an important element of our overall pharmaceutical business strategy we will focus our manufacturing activities on supporting future key areas of growth in which we aim to change the treatment paradigm for patients. All of our company’s new technology platforms and modalities will benefit from this investment.”.

Production 52

Production Pharmaceuticals Science Therapies 52

The Pharma Data

JULY 29, 2021

P-tau217 in blood showed promise as additional biomarker of efficacy- Donanemab treatment led to 24% lowering of P-tau217 from baseline. Food and Drug Administration (FDA) had granted Breakthrough Therapy designation for donanemab based on the Phase 2 data. In June 2021, Lilly announced the U.S.

Disease 52

Disease Pharmacokinetics Treatment FDA 52

The Pharma Data

FEBRUARY 21, 2022

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies.

Small Molecule 52

Small Molecule Clinical Trials Clinical Development Production 52

The Pharma Data

MARCH 9, 2021

Lilly will present detailed results of the TRAILBLAZER-ALZ phase 2 study, which showed that donanemab treatment resulted in significant slowing of decline in a composite measure of cognition and daily function in people with early symptomatic Alzheimer’s disease (AD) compared to placebo. About Avid Radiopharmaceuticals.

Disease 40

Disease International Research Therapies 40

The Pharma Data

SEPTEMBER 16, 2020

SLB linked to 2025 Patient Access Targets to increase patients reached in low- and middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagship Programs by 50%. Weak healthcare systems in LMICs also hinder timely diagnosis and treatment.

Regulations 52

Regulations Therapies Government Disease 52

DrugBank

AUGUST 9, 2024

However, searching for broader applicability and personalized approaches continues, as not all patients respond to these treatments. In 2021, an estimated 537 million adults were living with diabetes, a number projected to reach 643 million by 2030. billion by 2030. The market for cardiovascular drugs, valued at 155.6

Pharmaceuticals 78

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 78

The Pharma Data

AUGUST 5, 2021

approval; acquisition of Vividion Therapeutics agreed; start of first clinical study for Parkinson’s cell therapy treatment. Food and Drug Administration for the treatment of adult patients with chronic kidney disease and type 2 diabetes. Group sales increase by 12.9 percent (Fx & portfolio adj.) percent to 1.61

Production 52

Production Pharmaceuticals Science Therapies 52

Drug Discovery World

APRIL 10, 2024

With this heightened interest, insight into the current state of obesity research and its future direction is particularly valuable. An ICON survey of over 100 drug development professionals in obesity research revealed optimism about future therapies, with a significant shift towards combination treatments for obesity and its comorbidities.

Clinical Trials 130

Clinical Trials Trials Therapies Treatment 130